Stiripentol (marketed as Diacomit by Laboratoires Biocodex) is an anticonvulsant drug used in the treatment of epilepsy. It is approved for the treatment of Dravet syndrome, an epilepsy syndrome. Stiripentol increases GABAergic activity. At clinically relevant concentrations, it enhances central GABA neurotransmission through a barbiturate-like effect, since it increases the duration of opening of GABA-A receptor channels in hippocampal slices.
Hu, Aixi; Wu, Zhilin; Ye, Jiao. (Assignee Hunan University, Peop. Rep. China). Preparation method of stiripentol. CN 102690252. (2012).
Chang, Meng-Yang; Tsai, Chung-Yu; Wu, Ming-Hao. NBS-mediated cyclization of trans-cinnamic alcohols. Tetrahedron. Volume 69. Issue 31. Pages 6364-6370. Journal. 2013.
Han, Xing-Wang; Zhang, Tao; Zheng, Yan-Long; Yao, Wei-Wei; Li, Jiang-Fei; Pu, You-Ge; Ye, Mengchun; Zhou, Qi-Lin. Bronsted Acid Enabled Nickel-Catalyzed Hydroalkenylation of Aldehydes with Styrene and its Derivatives. Angewandte Chemie, International Edition. Volume 57. Issue 18. Pages 5068-5071. Journal. 2018.
Rao, Tadimeti; Zhang, Chengzhi. (Assignee Auspex Pharmaceuticals, Inc., USA). Preparation of deuterated stiripentol compounds as GABA aminotransferase inhibitors and/or GABA reuptake transporter. WO 2011011420. (2011).
